Literature DB >> 23149577

Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice.

Perrine Busquet1, Valeria Capurro, Andrea Cavalli, Daniele Piomelli, Angelo Reggiani, Rosalia Bertorelli.   

Abstract

We investigated a possible drug efficacy enhancement obtained by combining inactive doses of galantamine and memantine in the scopolamine-induced amnesia model in mice. We evaluated the effects of the two drugs, either alone or in combination, using the spontaneous alternation and object recognition tasks. In both tests, combination of low doses of galantamine (0.1 mg/kg, s.c.) and memantine (0.5 mg/kg, i.p.), which were sub-active per se, rescued the memory impairment induced by scopolamine (1 mg/kg, i.p.). The results suggest that combinations of galantamine and memantine might provide a more effective treatment of memory impairments in cognitive disorders than either drug used alone.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23149577     DOI: 10.1254/jphs.12166sc

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  9 in total

Review 1.  Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces.

Authors:  Michela Rosini; Elena Simoni; Anna Minarini; Carlo Melchiorre
Journal:  Neurochem Res       Date:  2014-02-04       Impact factor: 3.996

Review 2.  Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets.

Authors:  Md Sahab Uddin; Abdullah Al Mamun; Md Tanvir Kabir; Ghulam Md Ashraf; May N Bin-Jumah; Mohamed M Abdel-Daim
Journal:  Mol Neurobiol       Date:  2020-09-15       Impact factor: 5.590

3.  In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Disease.

Authors:  Angelo M Reggiani; Elena Simoni; Roberta Caporaso; Johann Meunier; Emeline Keller; Tangui Maurice; Anna Minarini; Michela Rosini; Andrea Cavalli
Journal:  Sci Rep       Date:  2016-09-09       Impact factor: 4.379

4.  Effects of rivastigmine and memantine alone and in combination on learning and memory in rats with scopolamine-induced amnesia.

Authors:  Peter Georgiev Yanev; Darinka Slavcheva Dimitrova; Damianka Peteva Getova-Spassova
Journal:  Open Med (Wars)       Date:  2015-09-24

5.  Inhibition of Connexin43 Hemichannels Impairs Spatial Short-Term Memory without Affecting Spatial Working Memory.

Authors:  Laura Walrave; Mathieu Vinken; Giulia Albertini; Dimitri De Bundel; Luc Leybaert; Ilse J Smolders
Journal:  Front Cell Neurosci       Date:  2016-12-20       Impact factor: 5.505

6.  Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity.

Authors:  Maju Mathew Koola; Agnieszka Nikiforuk; Anilkumar Pillai; Ajay K Parsaik
Journal:  J Geriatr Care Res       Date:  2018

7.  Potentiation of cognitive enhancer effects of Alzheimer's disease medication memantine by alpha7 nicotinic acetylcholine receptor agonist PHA-543613 in the Morris water maze task.

Authors:  Nóra Bruszt; Zsolt Kristóf Bali; Sai Ambika Tadepalli; Lili Veronika Nagy; István Hernádi
Journal:  Psychopharmacology (Berl)       Date:  2021-08-13       Impact factor: 4.415

8.  The Requirement of L-Type Voltage-Dependent Calcium Channel (L-VDCC) in the Rapid-Acting Antidepressant-Like Effects of Scopolamine in Mice.

Authors:  Hanjie Yu; Mengmeng Li; Xinbei Shen; Dan Lv; Xin Sun; Jinting Wang; Xinmei Gu; Jingning Hu; Chuang Wang
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

Review 9.  Expanding the Arsenal Against Huntington's Disease-Herbal Drugs and Their Nanoformulations.

Authors:  Sukriti Vishwas; Monica Gulati; Bhupinder Kapoor; Saurabh Gupta; Sachin Kumar Singh; Ankit Awasthi; Arzoo Khan; Aditya Goyal; Anil Bansal; Suman Baishnab; Thakur Gurjeet Singh; Sandeep Arora; Omji Porwal; Ankit Kumar; Vijay Kumar
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.